RU2017121002A - Ингибиторы CD38 и способы лечения - Google Patents
Ингибиторы CD38 и способы лечения Download PDFInfo
- Publication number
- RU2017121002A RU2017121002A RU2017121002A RU2017121002A RU2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- compound
- compound according
- disease
- condition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (14)
1. Соединение формулы I
где Q представляет собой О, NH, N(H)C(O) или C(O)N(H);
R1 представляет собой С1-5алкилS(O)2СН3 или С1-6алкил, где указанный алкил может содержать неразветвленные части, разветвленные части, циклоалкильные части, и где указанный С1-6алкил возможно замещен одним ОН или ОСН3, и где указанный С1-6алкил возможно дополнительно замещен атомами фтора в количестве от 1 до 3; и
R2 представляет собой Н, C1-3алкил или галоген.
2. Соединение, представляющее собой фармацевтически приемлемую соль соединения по п. 1.
3. Соединение по п. 1 или 2, где R2 представляет собой Н или Cl.
4. Соединение по п. 1 или 2, где R2 представляет собой Н.
5. Соединение по любому из пп. 1-4, где циклогексановое кольцо имеет транс-ориентацию, как показано ниже
6. Соединение
7. Способ лечения заболевания или состояния, при котором полезно увеличение уровня никотинамидадениндинуклеотида (NAD+), включающий введение соединения по любому из пп. 1-6.
8. Способ по п. 7, где указанное заболевание или состояние представляет собой неалкогольный стеатогепатит (NASH), хроническую обструктивную болезнь легких (COPD) или ревматоидный артрит (RA).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086844P | 2014-12-03 | 2014-12-03 | |
| US62/086,844 | 2014-12-03 | ||
| PCT/IB2015/058965 WO2016087975A1 (en) | 2014-12-03 | 2015-11-19 | Cd38 inhibitors and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017121002A true RU2017121002A (ru) | 2019-01-11 |
| RU2017121002A3 RU2017121002A3 (ru) | 2019-03-15 |
Family
ID=54708091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017121002A RU2017121002A (ru) | 2014-12-03 | 2015-11-19 | Ингибиторы CD38 и способы лечения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9840496B2 (ru) |
| EP (1) | EP3227275B1 (ru) |
| JP (1) | JP6550132B2 (ru) |
| KR (1) | KR20170090478A (ru) |
| CN (1) | CN107428733A (ru) |
| AU (1) | AU2015356721B2 (ru) |
| BR (1) | BR112017011642A2 (ru) |
| CA (1) | CA2969178A1 (ru) |
| ES (1) | ES2717260T3 (ru) |
| RU (1) | RU2017121002A (ru) |
| WO (1) | WO2016087975A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020504086A (ja) * | 2016-11-23 | 2020-02-06 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法 |
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| JP2022542396A (ja) * | 2019-07-31 | 2022-10-03 | ライボン・セラピューティクス・インコーポレイテッド | Ｃｄ３８の阻害剤としてのヘテロ二環式アミド |
| US20230025807A1 (en) | 2019-10-30 | 2023-01-26 | Mitobridge Inc. | Cd38 inhibitors |
| IL297128A (en) * | 2020-04-07 | 2022-12-01 | Mitobridge Inc | cd38 inhibitors |
| WO2022165114A1 (en) | 2021-01-29 | 2022-08-04 | Ribon Therapeutics, Inc. | Quinolines and azaquinolines as inhibitors of cd38 |
| KR20240001709A (ko) * | 2021-04-30 | 2024-01-03 | 난징 이뮤노파지 바이오테크 코., 엘티디. | 화합물 및 cd38 억제제로서의 용도 |
| CN117813296A (zh) * | 2021-07-12 | 2024-04-02 | 赛特凯恩蒂克公司 | Cd38调节剂和其使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1370139A4 (en) * | 2001-01-04 | 2010-09-22 | Einstein Coll Med | INHIBITORS OF ADP-RIBOSYL TRANSFERASES, CYCLASES, AND HYDROLASES, AND USES THEREOF |
| US7022680B2 (en) | 2002-05-30 | 2006-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases |
| EP2801573A1 (en) * | 2013-05-09 | 2014-11-12 | Sanofi | Hydantoine derivatives as CD38 inhibitors |
-
2015
- 2015-11-19 KR KR1020177018180A patent/KR20170090478A/ko unknown
- 2015-11-19 CN CN201580073761.2A patent/CN107428733A/zh active Pending
- 2015-11-19 EP EP15801951.3A patent/EP3227275B1/en active Active
- 2015-11-19 WO PCT/IB2015/058965 patent/WO2016087975A1/en active Application Filing
- 2015-11-19 RU RU2017121002A patent/RU2017121002A/ru not_active Application Discontinuation
- 2015-11-19 JP JP2017529357A patent/JP6550132B2/ja active Active
- 2015-11-19 CA CA2969178A patent/CA2969178A1/en not_active Abandoned
- 2015-11-19 AU AU2015356721A patent/AU2015356721B2/en not_active Ceased
- 2015-11-19 US US15/529,120 patent/US9840496B2/en active Active
- 2015-11-19 ES ES15801951T patent/ES2717260T3/es active Active
- 2015-11-19 BR BR112017011642A patent/BR112017011642A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP6550132B2 (ja) | 2019-07-24 |
| BR112017011642A2 (pt) | 2018-03-06 |
| JP2018501215A (ja) | 2018-01-18 |
| CN107428733A (zh) | 2017-12-01 |
| US9840496B2 (en) | 2017-12-12 |
| EP3227275A1 (en) | 2017-10-11 |
| AU2015356721B2 (en) | 2018-03-15 |
| WO2016087975A1 (en) | 2016-06-09 |
| EP3227275B1 (en) | 2019-01-02 |
| CA2969178A1 (en) | 2016-06-09 |
| ES2717260T3 (es) | 2019-06-20 |
| US20170260164A1 (en) | 2017-09-14 |
| AU2015356721A1 (en) | 2017-06-08 |
| KR20170090478A (ko) | 2017-08-07 |
| RU2017121002A3 (ru) | 2019-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017121002A (ru) | Ингибиторы CD38 и способы лечения | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
| JP2013523802A5 (ru) | ||
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| TN2017000204A1 (en) | Triazolopyrimidine compounds and uses thereof | |
| PE20161475A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| MD3882250T2 (ro) | Tetrahidropiranil-amino-pirolopirimidinona pentru utilizare într-un procedeu de tratament al unei tulburări mediate de BTK | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201691629A1 (ru) | Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения | |
| RU2016150410A (ru) | Ингибиторы фактора xia | |
| MA37712B1 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| JP2018501215A5 (ru) | ||
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| JP2017514910A5 (ru) | ||
| MX2016006199A (es) | Inhibidores de replicacion del virus de influenza. | |
| JP2015532645A5 (ru) | ||
| JP2017517512A5 (ru) | ||
| EA201691150A1 (ru) | Соединения изопропилтриазолопиридина | |
| RU2018113718A (ru) | Новые соединения | |
| EA201790337A1 (ru) | Кристаллические формы ингибиторов глутаминазы | |
| EA201490269A1 (ru) | Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета | |
| EA201790343A1 (ru) | Способ получения сульфамидных производных пиримидина | |
| EA201690879A1 (ru) | Новое триазолопиридиновое соединение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190701 |